← All trials
NCT05223478
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 17, 2021
- Primary completion
- Apr 18, 2022
- Completion date
- Apr 28, 2022
- First posted
- Feb 4, 2022
- Last posted
- Jun 22, 2022
- Enrollment
- 23
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ocuphire Pharma, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.